In recent developments, the Biden administration has resumed the distribution of taxpayer-funded at-home COVID test kits, allowing each family to receive up to four free tests per person after a $600 million investment in acquiring 200 million tests.
However, amidst the recent political frenzy over the removal of Kevin McCarthy as Speaker of the House, the FDA amended the Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine, despite the CDC declaring an end to the Public Health Emergency almost five months earlier.
This has raised questions about the basis for approving an EUA when, according to the CDC, the emergency no longer exists. The FDA cites a public health emergency determination made by the Secretary of Health and Human Services as the grounds for this authorization.
Meanwhile, there is growing concern among health professionals about various anomalies since the release of the COVID-19 vaccines. Issues like “turbo cancers,” significant spikes in excess mortality, and the discovery of mysterious white fibrous clots in cadavers are being reported.
Additionally, Pfizer and Moderna’s COVID-19 mRNA vaccines are allegedly associated with a 42% excess mortality rate in individuals aged 0-24, according to Dr. William Makis.
Despite these concerns, the federal government continues to allocate significant resources to perpetuate COVID-19 testing and Emergency Use Authorization for vaccines. Notably, the FDA recently updated the emergency use authorization of the Novavax COVID-19 Vaccine, Adjuvanted, to include the 2023-2024 formula. This formulation now covers the spike protein from the SARS-CoV-2 Omicron variant lineage XBB.1.5.
The original monovalent version is no longer authorized for use in the United States. The Novavax vaccine, in its 2023-2024 Formula, is approved for individuals aged 12 and above, with specific dosing guidelines provided based on vaccination history and immunocompromised status.